Summary
A longitudinal cohort of research participants and data with two, one and no copies of the APOE4 gene, reflecting three levels of genetic risk for AD, including a sub-set of subjects with extensive brain imaging and other biomarker data. Participants are cognitively unimpaired and are followed every two years with UDS, cognitive assessments, biospecimens and a subset undergoing imaging. Participants are seen at Mayo Scottsdale and Banner Alzheimer's Institute in Scottsdale and Phoenix AZ, USA
About This Data Partner
With support from NIA, the state of Arizona and Mayo Clinic and BAI, the Arizona APOE4 Gene Dose Program provides a longitudinal cohort of research participants and data with two, one and no copies of the APOE4 gene, reflecting three levels of genetic risk for AD, including a sub-set of subjects with extensive brain imaging and other biomarker data. This program has made pioneering contributions to the conceptualization of "preclinical AD," established a foundation for the Alzheimer's Prevention Initiative (API) and the accelerated evaluation of prevention therapies, and includes an invaluable resource of data and samples to help researchers detect and track the earliest biomarker and cognitive changes associated with AD, contribute to the understanding of genetic and non-genetic risk factors, develop data analysis techniques with improved power to detect and track AD and evaluate promising but unproven AD prevention therapies.
Additional Information
Principal Investigator(s)
Eric Reiman and Rick Caselli
Contact Phone
1-888-786-7259
Data Available
UDS, cognitive assessments, biospecimens, MRI (T1, rsf, DTI, Flair) and PET (FDG, PiB, Florbetapir, AV-1451)